GLP-1 receptor agonists have changed the conversation around weight management more dramatically than any class of medication in decades. Tirzepatide and semaglutide, the active compounds behind Mounjaro, Zepbound, Ozempic, and Wegovy, produce weight loss outcomes once achievable only through bariatric surgery. Clinical trials have shown total body weight reductions of 15 to 22 percent, and for millions of people living with obesity or metabolic disease, that is genuinely lif

Every January, every summer, and every time a wedding or reunion appears on the calendar, the same question resurfaces: how fast can I lose this weight? It is a reasonable question, and it is one most physicians have heard hundreds of times. The problem is that it is the wrong question. The right question is not how fast you can lose weight. It is how fast you should, and what you stand to lose if you push beyond what your body is designed to handle. Weight loss that happens

In 2025, the idea of “dieting hard” no longer dominates the conversation. Instead, people are asking: What actually works; safely,...

As Ozempic (semaglutide) and other GLP-1 weight loss medications like Wegovy and Mounjaro gain popularity, a new concern has emerged:...